Epidiolex (cannabidiol) Vs FDA
Brand name: Epidiolex
Generic name: cannabidiol
Company: GW Pharmaceuticals
plc
Treatment for: Lennox-Gastaut
Syndrome, Dravet Syndrome
Epidiolex (cannabidiol) is a
cannabinoid product in development for the treatment
of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet
syndrome.
Marijuana-derived
drug for epilepsy gets FDA committee recommendation
Epidiolex,
an oral solution, for the treatment of serious types of epilepsy. The FDA has
endorsed engineered variants of some cannabinoid chemicals found in the marijuana
plant for different purposes, including tumor relief from discomfort.
Cannabidiol,
additionally called CBD, is one of in excess of 80 dynamic cannabinoid
chemicals.
Epidiolex,
GW's lead cannabinoid product candidate, was produced for serious,
early-beginning epilepsy disorders, including Dravet disorder, an uncommon
hereditary brokenness of the cerebrum that starts in the main year of life;
Lennox-Gastaut disorder, a kind of epilepsy with various sorts of seizures; and
tuberous
sclerosis perplexing and childish fits, both of which start in earliest
stages and cause a sudden hardening of the body, arms and legs with the head
bowed forward.
Cannabis-derived drug clears hurdle on path to FDA
approval
Epidiolex would be the primary medication on the U.S. showcase got from the cannabis plant.
An outside board of counsellors to the FDA gave a consistent
vote of endorsemen.
The prescription, which is made by GW Pharmaceuticals, is
utilized as a part of the treatment of seizures related with child
epilepsy.
The pharmaceutical's dynamic fixing cannabidiol is gotten
from the cannabis plant. Epidiolex does not contain THC and does not give
patients any psychoactive impacts. The FDA has effectively affirmed engineered
cannabinoids to lighten the reactions of medications, for example,
chemotherapy.
Comments
Post a Comment